New biologic therapeutics for ulcerative colitis and Crohn's disease

Bibliography

• Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:597-605
   PubMedGoogle Scholar
• Walsh A, Mabee J, Trivedi K. Inflammatory bowel disease. Prim Care 2011;38:415-32
   PubMed Web of Science ®Google Scholar
• Xavier RJ, Podilsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34
   PubMed Web of Science ®Google Scholar
• Nikfar S, Rahimi R, Rezaie A, et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54:1157-70
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009;54:712-21
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:590-9
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007;61:75-80
   PubMed Web of Science ®Google Scholar
• Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 2010;16:3684-98
   PubMed Web of Science ®Google Scholar
• Ehteshami-Afshar S, Nikfar S, Rezaie A, et al. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 2011;7:1000-12
   PubMed Web of Science ®Google Scholar
• Abdolghaffari AH, Nikfar S, Rahimi HR, et al. A comprehensive review of antibiotics in clinical trials for inflammatory bowel disease. Int J Pharmacol 2012;8:596-613
   Google Scholar
• Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010;6:49-55
   PubMed Web of Science ®Google Scholar
• Rezaie A, Eshghtork A, Zamani M, et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta1 in relation to disease activity in Crohn's disease patients. Ann NY Acad Sci 2006;1091:110-22
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008;4:185-90
   Web of Science ®Google Scholar
• Müllner K, Miheller P, Herszényi L, Tulassay Z. Probiotics in the Management of Crohn's Disease and Ulcerative Colitis. Curr Pharm Des 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Salari P, Abdollahi M. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012;21:261-4
   PubMed Web of Science ®Google Scholar
• Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008;7:129-35
   PubMedGoogle Scholar
• Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: role of ATP. Recent Patents Endocr Metabol Immune Drug Discov 2009;3:69-75
   Google Scholar
• Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des 2011;17:4372-8
   PubMed Web of Science ®Google Scholar
• Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009;54:471-80
   PubMed Web of Science ®Google Scholar
• Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010;16:4504-14
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24
   PubMed Web of Science ®Google Scholar
• Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007;52:2015-21
   PubMed Web of Science ®Google Scholar
• Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: role of ATP. Recent Patents Endocr Metab Immune Drug Discov 2009;3:69-75
   Google Scholar
• Dahan S, Roth-Walter F, Arnaboldi P, et al. Epithelia: lymphocyte interactions in the gut. Immunol Rev 2007;215:243-53
   PubMed Web of Science ®Google Scholar
• Rezaie A, Taghavi Bayat B, Abdollahi M. Biologic Management of Fistulizing Crohn's Disease. Int J Pharmacol 2005;1:17-24
   Google Scholar
• Neurath MF. IL-23: a master regulator in Crohn's disease. Nat Med 2007;13:26-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 2001;123:255-60
   Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9
   PubMed Web of Science ®Google Scholar
• Miheller P, Lakatos PL, Horváth G, et al. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe–a Hungarian nationwide observational study. BMC Gastroenterol 2009;9:66
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Colombo E, Maconi G, et al. Infliximab in treatment of Crohn's disease: the Milan experience. Dig Liver Dis 2002;34:411-18
   PubMedGoogle Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012;143:62-9
   PubMed Web of Science ®Google Scholar
• Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
   PubMed Web of Science ®Google Scholar
• Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010;13:472-81
   PubMed Web of Science ®Google Scholar
• Keshav S, Vaňásek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One 2013;8:e60094
   PubMed Web of Science ®Google Scholar
• Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520-6
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204-13
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
   PubMed Web of Science ®Google Scholar
• Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65
   PubMed Web of Science ®Google Scholar
• Nikfar S, Ehteshami-Afshar S, Abdollahi M. Is certolizumab pegol safe and effective in the treatment of patients with moderate to severe Crohn's disease? A meta-analysis of controlled clinical trials. Iran Red Crescent Med J 2013;15:668-75
   Web of Science ®Google Scholar
• Hanauer SB, Panes J, Colombel JF, et al. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-93
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9:670-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8:696-702
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen OØ, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-95
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF-alpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:888-93
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
   PubMed Web of Science ®Google Scholar
• Feagan B, Sandborn W, Marano C, et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. CDDW/Annual CASL; 1 - 4 March 2013; Victoria, British Columbia
   Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Hass S, et al. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 2007;102:2737-46
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7integrin. N Engl J Med 2005;352:2499-507
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7
   PubMed Web of Science ®Google Scholar
• Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012;143:62-9
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82
   PubMed Web of Science ®Google Scholar
• Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13:2-11
   PubMed Web of Science ®Google Scholar
• Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46
   PubMed Web of Science ®Google Scholar
• Yacyshyn BR, Chey WY, Goff J, et al. Double-blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, c (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6
   PubMed Web of Science ®Google Scholar
• Van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double-bind, escalating dose study of alicaforsen enema in ulcerative colitis. Gut 2004;53:1646-51
   PubMed Web of Science ®Google Scholar
• Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009;104:1976-83
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008;23:289-96
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50
   PubMed Web of Science ®Google Scholar
• Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204-13
   PubMed Web of Science ®Google Scholar
• Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20:1337-46
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18
   PubMed Web of Science ®Google Scholar
• Schreiber S, Lawrance IC, Thomsen OØ, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011;33:185-93
   PubMed Web of Science ®Google Scholar
• Feagan BG, Hanauer SB, Coteur G, Schreiber S. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther 2011;33:1143-51
   PubMed Web of Science ®Google Scholar
• Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8
   PubMed Web of Science ®Google Scholar
• A safety and effectiveness study of golimumab in Japanese patients with Moderately to Severely Active Ulcerative Colitis. Janssen Pharmaceutical K.K. 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT01863771?term=NCT01863771&rank=1
   Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109
   PubMed Web of Science ®Google Scholar
• An Efficacy and Safety Study of Golimumab in Participants with Ulcerative Colitis. Janssen Research & Development, LLC. 2007. Available from: http://clinicaltrial.gov/ct2/show/NCT00488774?term=NCT00488774&rank=1
   Google Scholar
• Safety and Efficacy of Natalizumab in Combination with Remicade in the Treatment of Crohn's Disease. Elan Pharmaceuticals. 2003. Available from: http://clinicaltrial.gov/ct2/show/NCT00055536?term=NCT00055536&rank=1
   Google Scholar
• Safety, Tolerability and Effectiveness of Natalizumab in Adolescents with Active Crohn's Disease. Elan Pharmaceuticals. 2003. Available from: http://clinicaltrial.gov/ct2/show/NCT00055367?term=NCT00055367&rank=1
   Google Scholar
• A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease. Elan Pharmaceuticals. 2004. Available from: http://clinicaltrial.gov/ct2/show/NCT00078611?term=NCT00078611&rank=1
   Google Scholar
• Study of Vedolizumab in Patients with Moderate to Severe Crohn's Disease (GEMINI III). Millennium Pharmaceuticals, Inc. 2010. Available from: http://clinicaltrial.gov/ct2/show/NCT01224171?term=NCT01224171&rank=1
   Google Scholar
• An Open-label Study of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease (GEMINI LTS). Millennium Pharmaceuticals, Inc. 2008. Available from: http://clinicaltrial.gov/ct2/show/NCT00790933?term=NCT00790933&rank=1
   Google Scholar
• Esmaily H, Vaziri-Bami A, Miroliaee AE, et al. The correlation between NF-kappaB inhibition and disease activity by co-administration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011;25:723-33
   PubMed Web of Science ®Google Scholar